Chemical formula: C₄₅H₅₀ClN₇O₇S Molecular mass: 868.45 g/mol PubChem compound: 49846579
Venetoclax is indicated for:
Population group: only adults (18 years old or older)
Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Venetoclax in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
Venetoclax monotherapy is indicated for the treatment of CLL:
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Venetoclax in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Venetoclax is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.